Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists

被引：19

作者：

Shah, Unmesh ^{[1
]}

Boyle, Craig D. ^{[1
]}

Chackalamannil, Samuel ^{[1
]}

Neustadt, Bernard R. ^{[1
]}

Lindo, Neil ^{[1
]}

Greenlee, William J. ^{[1
]}

Foster, Carolyn ^{[1
]}

Arik, Leyla ^{[1
]}

Zhai, Ying ^{[1
]}

Ng, Kwokei ^{[1
]}

Wang, Shiyong ^{[1
]}

Monopoli, Angela ^{[1
]}

Lachowicz, Jean E. ^{[1
]}

机构：

[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2008年 / 18卷 / 14期

关键词：

adenosine; A(2A); A(2A) receptor; A(2A) antagonist; A(2A) receptor antagonist; SCH; 58261; Parkinson's Disease;

D O I：

10.1016/j.bmcl.2008.05.074

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SCH 58261 is a reported adenosine A(2A) receptor antagonist, which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. We report the design and synthesis of biaryl and heteroaryl analogs of SCH 58261 which improve the A(2A) receptor binding selectivity as well as the pharmacokinetic properties of SCH 58261. In particular, the quinoline 25 has excellent A(2A) receptor in vitro binding affinity and selectivity, sustained rat plasma levels upon oral dosing, and is active orally in a rat behavioral assay. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：4199 / 4203

页数：5

共 50 条

[41] Medicinal chemistry of A2A adenosine receptor antagonists
Caceiari, B
Pastorin, G
Spalluto, G
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (04) : 403 - 411
[42] Adenosine A2A Receptor Antagonists for Cancer Immunotherapy
Yu, Fazhi
Zhu, Chenyu
Xie, Qiong
Wang, Yonghui
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (21) : 12196 - 12212
[43] An efficient route to xanthine based A2A adenosine receptor antagonists and functional derivatives
LaBeaume, Paul
Dong, Ma
Sitkovsky, Michail
Jones, Elizabeth V.
Thomas, Rhiannon
Sadler, Sara
Kallmerten, Amy E.
Jones, Graham B.
[J]. ORGANIC & BIOMOLECULAR CHEMISTRY, 2010, 8 (18) : 4155 - 4157
[44] HQSAR and molecular docking studies of furanyl derivatives as adenosine A2A receptor antagonists
Camila Muñoz-Gutiérrez
Julio Caballero
Alejandro Morales-Bayuelo
[J]. Medicinal Chemistry Research, 2016, 25 : 1316 - 1328
[45] HQSAR and molecular docking studies of furanyl derivatives as adenosine A2A receptor antagonists
Munoz-Gutierrez, Camila
Caballero, Julio
Morales-Bayuelo, Alejandro
[J]. MEDICINAL CHEMISTRY RESEARCH, 2016, 25 (07) : 1316 - 1328
[46] Inhibition of monoamine oxidase B by selective A2A adenosine receptor antagonists.
Castagnoli, N
Petzer, JP
Castagnoli, K
Schwarzschild, MA
Chen, JF
[J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2002, 15 (12) : 1663 - 1663
[47] Inhibition of monoamine oxidase B by selective A2A adenosine receptor antagonists.
Castagnoli, N
Petzer, JP
Castagnoli, K
Schwarzschild, MA
Chen, JF
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U369 - U369
[48] New substituted 9-propyladenine derivatives as A2A adenosine receptor antagonists
Lambertucci, C.
Buccioni, M.
Dal Ben, D.
Kachler, S.
Marucci, G.
Spinaci, A.
Thomas, A.
Klotz, K. -N.
Volpini, R.
[J]. MEDCHEMCOMM, 2015, 6 (05) : 963 - 970
[49] [3H]-SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes
Varani, K
Gessi, S
Dionisotti, S
Ongini, E
Borea, PA
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (08) : 1723 - 1731
[50] Down-regulation of A2A coronary adenosine receptors by ZM-241385 and SCH-58261.
Rekik, M
Mustafa, SJ
[J]. FASEB JOURNAL, 2000, 14 (04): : A165 - A165

← 1 2 3 4 5 →